Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:02am, Monday, 22'nd Jun 2026
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
07:30am, Monday, 22'nd Jun 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Ca
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
10:16am, Friday, 12'th Jun 2026
OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.
Organon wins US approval to widen use of arthritis biosimilar drug
08:44am, Wednesday, 10'th Jun 2026
Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a life‑threatening immune reactio
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 09'th Jun 2026
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
01:13pm, Thursday, 04'th Jun 2026
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
11:16am, Thursday, 04'th Jun 2026
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)
12:04pm, Tuesday, 02'nd Jun 2026
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:01am, Friday, 29'th May 2026
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Orogen Reports Strong Q1 2026 Results with 144% Growth in Net Income
07:30am, Tuesday, 26'th May 2026
VANCOUVER, BC / ACCESS Newswire / May 26, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to report record revenue and after-tax profit for the three-month
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
05:06am, Thursday, 21'st May 2026
Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon's Malaysia office to discu
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:00am, Monday, 18'th May 2026
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon to Present New Research on Access and Value at ISPOR 2026
08:00am, Friday, 15'th May 2026
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data acros
Organon to Present New Research on Access and Value at ISPOR 2026
07:30am, Friday, 15'th May 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women's health, biosimilar and general medicines portfolio at ISPOR 2026.
